Posted by Michael Wonder on 20 Dec 2021
EMA adopts a positive CHMP opinion for Pfizer’s and OPKO’s somatrogon, a long-acting treatment for paediatric growth hormone deficiency
17 December 2021 - If approved by the European Commission, somatrogon will offer children and adolescents living with growth hormone deficiency a once weekly treatment option resulting in fewer doses per year compared to daily treatment options.
Pfizer announced today that the CHMP of the EMA has adopted a positive opinion recommending somatrogon, a once weekly long-acting recombinant human growth hormone, for marketing authorisation to treat children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone.
